retatrutide weight loss clinical trials retatrutide Phase III study demonstrates 30% The trillion-dollar peptide. Appearing on

In December 2024, Eli Lilly, the US pharmaceutical giant, announced the launch of its blockbuster drug, Tirzepatide, in India in 2025

To understand the durability and stability of weight outcomes after stopping GLP-1s, we studied 188,722 patients who stopped using a GLP-1 medication after being on it for at least 90 days and who lost at least 5 pounds while on it

There are many semaglutide drugs and GLP-1 agonists that have been recently covered in the media, but we will only discuss Ozempic in this article

Advanced GLP-1 Science: Genetic Pathways and Personalized Response Not all people respond identically to GLP-1 therapy because genetic variation affects how your body processes these medications and regulates appetite signals

Not a tacked-on upsell

Impact on Early Treatment Decisions As these oral GLP-1 therapies become easier to use, clinicians are reconsidering when to start treatment